CN101945671B - 用于水溶性阳离子两亲性的药用活性物质给药的药物递送系统 - Google Patents

用于水溶性阳离子两亲性的药用活性物质给药的药物递送系统 Download PDF

Info

Publication number
CN101945671B
CN101945671B CN2008801270941A CN200880127094A CN101945671B CN 101945671 B CN101945671 B CN 101945671B CN 2008801270941 A CN2008801270941 A CN 2008801270941A CN 200880127094 A CN200880127094 A CN 200880127094A CN 101945671 B CN101945671 B CN 101945671B
Authority
CN
China
Prior art keywords
retinoyl
methyl ester
delivery system
drug delivery
sodium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801270941A
Other languages
English (en)
Chinese (zh)
Other versions
CN101945671A (zh
Inventor
朱莉安·阿列克索夫
伊戈尔·洛科特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oswald Mia Pharmaceutical Co
Original Assignee
Ardenia Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardenia Investments Ltd filed Critical Ardenia Investments Ltd
Publication of CN101945671A publication Critical patent/CN101945671A/zh
Application granted granted Critical
Publication of CN101945671B publication Critical patent/CN101945671B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008801270941A 2007-12-19 2008-12-18 用于水溶性阳离子两亲性的药用活性物质给药的药物递送系统 Expired - Fee Related CN101945671B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SEPCT/SE2007/001128 2007-12-19
PCT/SE2007/001128 WO2009078755A1 (en) 2007-12-19 2007-12-19 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
PCT/SE2008/051517 WO2009078804A1 (en) 2007-12-19 2008-12-18 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance

Publications (2)

Publication Number Publication Date
CN101945671A CN101945671A (zh) 2011-01-12
CN101945671B true CN101945671B (zh) 2012-08-22

Family

ID=40795733

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801270941A Expired - Fee Related CN101945671B (zh) 2007-12-19 2008-12-18 用于水溶性阳离子两亲性的药用活性物质给药的药物递送系统

Country Status (23)

Country Link
US (1) US8324274B2 (enExample)
EP (1) EP2231193B1 (enExample)
JP (1) JP5466174B2 (enExample)
KR (1) KR101616135B1 (enExample)
CN (1) CN101945671B (enExample)
AU (1) AU2008339101B2 (enExample)
BR (1) BRPI0821739B8 (enExample)
CA (1) CA2709268C (enExample)
CY (1) CY1121145T1 (enExample)
DK (1) DK2231193T3 (enExample)
EA (1) EA018559B1 (enExample)
ES (1) ES2689509T3 (enExample)
HR (1) HRP20181517T1 (enExample)
HU (1) HUE039695T2 (enExample)
LT (1) LT2231193T (enExample)
MX (1) MX2010006906A (enExample)
MY (1) MY150820A (enExample)
NZ (1) NZ586858A (enExample)
PL (1) PL2231193T3 (enExample)
PT (1) PT2231193T (enExample)
SI (1) SI2231193T1 (enExample)
WO (2) WO2009078755A1 (enExample)
ZA (1) ZA201004992B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
CA2865011C (en) 2012-02-29 2021-06-15 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
CN112239418B (zh) * 2019-07-18 2023-07-07 上海现代药物制剂工程研究中心有限公司 视黄醇类化合物及其钠盐的制备方法
CN112321465B (zh) 2019-07-18 2023-06-06 上海现代药物制剂工程研究中心有限公司 一种含苯基化合物、其中间体、制备方法及应用
CN115212220A (zh) * 2021-04-16 2022-10-21 上海现代药物制剂工程研究中心有限公司 一种药物递送系统及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
WO2002092600A1 (en) * 2001-05-15 2002-11-21 Ardenia Investments Ltd. Retinol derivatives potentiation of active substances by micellar preparation
US20040048923A1 (en) * 2002-07-23 2004-03-11 Oleg Strelchenok Therapeutic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1041889B (zh) * 1999-03-11 2005-03-18 阿登尼亚投资有限公司 治疗癌症的新化合物
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
KR100566911B1 (ko) * 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
JP2004010479A (ja) * 2002-06-03 2004-01-15 Japan Science & Technology Corp ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法
JP2006199590A (ja) * 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
US20050196343A1 (en) * 2004-02-27 2005-09-08 Molecular Therapeutics, Inc. Degradable nanoparticles
US8945629B2 (en) * 2004-09-10 2015-02-03 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
WO2009078756A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
WO2009078754A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
WO2002092600A1 (en) * 2001-05-15 2002-11-21 Ardenia Investments Ltd. Retinol derivatives potentiation of active substances by micellar preparation
US20040048923A1 (en) * 2002-07-23 2004-03-11 Oleg Strelchenok Therapeutic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
实施例16-17，24-25，32-33，53，60-62，64，66，权利要求1-49.

Also Published As

Publication number Publication date
LT2231193T (lt) 2018-11-12
WO2009078804A1 (en) 2009-06-25
AU2008339101B2 (en) 2015-08-06
EA018559B1 (ru) 2013-08-30
CA2709268C (en) 2016-02-09
JP2011507840A (ja) 2011-03-10
PT2231193T (pt) 2018-11-02
EP2231193A1 (en) 2010-09-29
ES2689509T3 (es) 2018-11-14
JP5466174B2 (ja) 2014-04-09
BRPI0821739B1 (pt) 2021-03-02
EP2231193A4 (en) 2014-12-03
CA2709268A1 (en) 2009-06-25
US8324274B2 (en) 2012-12-04
DK2231193T3 (en) 2018-10-22
AU2008339101A1 (en) 2009-06-25
ZA201004992B (en) 2011-03-30
EP2231193B1 (en) 2018-07-18
BRPI0821739A2 (pt) 2015-06-16
CY1121145T1 (el) 2020-05-29
EA201070626A1 (ru) 2010-12-30
HUE039695T2 (hu) 2019-01-28
MX2010006906A (es) 2010-11-10
KR20100099290A (ko) 2010-09-10
NZ586858A (en) 2012-06-29
US20110236472A1 (en) 2011-09-29
PL2231193T3 (pl) 2019-01-31
KR101616135B1 (ko) 2016-04-27
HRP20181517T1 (hr) 2018-11-30
SI2231193T1 (sl) 2018-12-31
WO2009078755A1 (en) 2009-06-25
CN101945671A (zh) 2011-01-12
BRPI0821739B8 (pt) 2021-05-25
MY150820A (en) 2014-02-28

Similar Documents

Publication Publication Date Title
CN101951956B (zh) 用于水溶性差的药用活性物质给药的药物递送系统
Varshosaz et al. Retinoic Acid Decorated Albumin‐Chitosan Nanoparticles for Targeted Delivery of Doxorubicin Hydrochloride in Hepatocellular Carcinoma
CN103110957A (zh) 一种氧化石墨烯药物载体及其制备方法和应用
JP5466174B2 (ja) 水溶性、カチオン性および両親媒性の薬学的に活性な物質を投与するためのドラッグ・デリバリー・システム
CN101945670B (zh) 用于水溶性阳离子两亲性药用活性物质给药的药物递送系统
Aldeeb et al. Emerging trends in the application of nanosuspension-based biomaterials for anticancer drug delivery
CN102552154B (zh) 蒽环类抗肿瘤抗生素油酸复合物的白蛋白纳米粒制剂
Abdulbaqi Loading of clarithromycin and paclitaxel on prepared Cds/nio nanoparticles as promising nanocarriers
Varshosaz et al. Research Article Retinoic Acid Decorated Albumin-Chitosan Nanoparticles for Targeted Delivery of Doxorubicin Hydrochloride in Hepatocellular Carcinoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20210429

Address after: uppsala

Patentee after: Oswald MIA pharmaceutical Co.

Address before: London, England

Patentee before: ARDENIA INVESTMENTS, Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120822

CF01 Termination of patent right due to non-payment of annual fee